Name: 4-PBA (Sodium Phenylbutyrate)
Brand: Selleck Chemicals
SKU: S4125
Rating: 5 (23 reviews)

Spring naar

Kwaliteitscontrole (Quality Control)

Batch: Zuiverheid: 99.99%

99.99

Gerelateerde doelwitten	PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF
Overig HDAC Inhibitoren	ITF-2357 (Givinostat) Hydrochloride Monohydrate Fimepinostat (CUDC-907) Trichostatin A (TSA) Entinostat (MS-275) RGFP966 Quisinostat (JNJ-26481585) Dihydrochloride Tubastatin A Hydrochloride Tubastatin A Mocetinostat (MGCD0103) Ricolinostat (ACY-1215)

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)

Cellijnen	Assaytype	Concentratie	Incubatietijd	Activiteitsbeschrijving	PMID
Hela	Function assay			Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay, Ki=6.34μM	19520580
U937	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human U937 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of CAMP mRNA expression in human VA10 cells at 4 mM after 24 hrs by RT-PCR analysis	19770273
HT-29	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human HT-29 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
A498	Function assay	4 mM	8 to 48 hrs	Induction of CAMP mRNA expression in human A498 cells at 4 mM after 8 to 48 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of DEFB1 mRNA expression in human VA10 cells at 4 mM after 24 hrs by RT-PCR analysis	19770273
VA10	Function assay	4 mM	24 hrs	Induction of LL-37 protein expression in human VA10 cells at 4 mM after 24 hrs by Western blotting	19770273
VA10	Function assay	20 nM	24 hrs	Induction of LL-37 protein expression in human VA10 cells at 20 nM after 24 hrs by Western blotting	19770273
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Molecuulgewicht	187.19	Formule	C₁₀H₁₁O₂.Na	Opslag (vanaf de datum van ontvangst)	3 jaar-20°Cpoeder
CAS-nr.	1716-12-7	SDF downloaden		Opslag van stamoplossingen	1 jaar-80°Cin oplosmiddel 1 maand-20°Cin oplosmiddel
Synoniemen	4-Phenylbutyric acid, NaPB			Smiles	C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]

Oplosbaarheid (Solubility)

In vitro
Batch:

DMSO : 37 mg/mL (197.66 mM)
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : 37 mg/mL

Ethanol : Insoluble

DMSO : 94 mg/mL (502.16 mM) Verwarmd met een waterbad van 60°C; Geultrasoneerd;
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : 37 mg/mL

Ethanol : Insoluble

Molariteitscalculator

Massa	Concentratie	Volume	Molecuulgewicht
=	×	×

Verdunningscalculator Molecuulgewichtcalculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Gevalideerd door Selleck labs. Mocht u aanpassingen aan deze formulering nodig hebben, neem dan contact op met ons verkoopteam voor aangepaste tests.	1.850mg/ml (9.88mM)	Taking the 1 mL working solution as an example, add 50 μL of 37 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

Dosering: mg/kg Gemiddeld gewicht van dieren: g Doseervolume per dier:μL Aantal dieren:

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH₂O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme (Mechanism of Action)

Targets/IC₅₀/Ki	HDAC
In vitro	4-PBA (Sodium Phenylbutyrate) is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. It significantly attenuates MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. This compound also attenuates the expression of the apoptosis antagonist Bcl-X(L), the double-strand break repair protein DNA-dependent protein kinase, the prostate progression marker caveolin-1, and the pro-angiogenic vascular endothelial growth factor in prostate cancer cells. It is found to act in synergy with ionizing radiation to induce apoptosis in prostate cancer cells.
In vivo	4-PBA (Sodium Phenylbutyrate) significantly extends survival and improved both the clinical and neuropathological phenotypes in G93A transgenic ALS mice. This compound ameliorates histone hypoacetylation observed in G93A mice and induced expression of nuclear factor-kappaB (NF-kappaB) p50, the phosphorylated inhibitory subunit of NF-kappaB (pIkappaB) and beta cell lymphoma 2 (bcl-2), but reduced cytochrome c and caspase expression. It acts to phosphorylate IkappaB, translocating NF-kappaB p50 to the nucleus, or to directly acetylate NF-kappaB p50. It also increases brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots in a transgenic mousemodel of Huntington's disease (HD). The compound increases mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum.
Referenties	[1] https://pubmed.ncbi.nlm.nih.gov/15626823/ [2] https://pubmed.ncbi.nlm.nih.gov/11571633/ [3] https://pubmed.ncbi.nlm.nih.gov/15934930/ [4] https://pubmed.ncbi.nlm.nih.gov/15494404/ [5] https://pubmed.ncbi.nlm.nih.gov/34716302/ [6] https://pubmed.ncbi.nlm.nih.gov/28649223/

Toepassingen (Applications)

Methoden	Biomarkers	Afbeeldingen	PMID
Western blot	Survivin p38 / p-p38 / ERK / p-ERK / JNK / p-JNK		27274278

Informatie over klinische proeven (Clinical Trial Information)

(gegevens van https://clinicaltrials.gov, bijgewerkt op 2026-07-06)

NCT-nummer	Werving	Aandoeningen	Sponsor/medewerkers	Startdatum	Fasen
NCT06069375	SUSPENDED	Medium-chain Acyl-CoA Dehydrogenase Deficiency	Jerry Vockley, MD, PhD	2024-04-01	PHASE2
NCT06645769	NOT_YET_RECRUITING	Diabetes	University of Pennsylvania	2027-06-01	EARLY_PHASE1
NCT07125066	ENROLLING_BY_INVITATION	Combined D,L-2-hydroxyglutaric Aciduria	Jerry Vockley, MD, PhD	2025-07-30	PHASE1
NCT06773026	RECRUITING	Medium-chain Acyl-CoA Dehydrogenase Deficiency	Jerry Vockley, MD, PhD	2025-06-30	PHASE2
NCT05983588	Recruiting	Corticobasal Syndrome (CBS)	Technical University of Munich	2023-12-12	Phase 2
NCT05028803	COMPLETED	Obese Non Diabetic	University of Nottingham	2021-09-01

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

4-PBA (Sodium Phenylbutyrate) HDAC Remmer

Molecuulgewicht: 187.19

Kwaliteitscontrole (Quality Control)

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Oplosbaarheid (Solubility)

Molariteitscalculator

In vivo formulatiecalculator (heldere oplossing)

Werkingsmechanisme (Mechanism of Action)

Toepassingen (Applications)

Informatie over klinische proeven (Clinical Trial Information)

4-PBA (Sodium Phenylbutyrate) HDAC Remmer

Molecuulgewicht: 187.19

Kwaliteitscontrole (Quality Control)

Celkweek, behandeling & werkzame concentratie (Cell Culture, Treatment & Working Concentration)

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Oplosbaarheid (Solubility)

Molariteitscalculator

In vivo formulatiecalculator (heldere oplossing)

Werkingsmechanisme (Mechanism of Action)

Toepassingen (Applications)

Informatie over klinische proeven (Clinical Trial Information)

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)